Sanara MedTech Inc. (SMTI) SEC Filings & Earnings Calls

Regulatory delay risk: FTC second request may delay or block merger.

“Second Request extends waiting period; merger completion subject to HSR clearance.”

Antitrust review ongoing; HSR waiting period extended to Oct 15, 2026.

“MiMedx voluntarily withdrew and refiled HSR notification, commencing a new 30-day waiting period expiring Oct 15, 2026.”

Merger completion risk

“The closing of the Merger is subject to the satisfaction of various customary closing conditions, including, among others, the adoption and approval of the Merger Agreement by our shareholders, and a registration statement on Form S-4 being declared effective by the Securities and Exchange Commission (the “SEC”) and receipt of required regulatory approvals, ” · word for word

Operating income declined 28% YoY due to higher SG&A expenses from strategic initiatives.

“Operating income of $1.8 million, compared to operating income of $2.5 million in the second quarter of 2025.” · word for word

Net loss from continuing operations of $0.4 million vs net income of $0.5 million YoY.

“Net loss from continuing operations of $0.4 million, or a loss of $0.05 per diluted share, compared to net income from continuing operations of $0.5 million, or $0.05 per diluted share.” · word for word

Transaction subject to shareholder and regulatory approvals; closing risk.

“subject to approval by Sanara shareholders, the receipt of required regulatory approvals and other customary closing conditions.” · word for word

Integration risk; achieving cost synergies and revenue targets.

“Anticipates Over $20 Million in Run-Rate Cost Synergies.” · word for word

High debt and interest burden

“Interest expense $1.8M in Q1 2026; debt $46.2M at 13.25% rate.”

Concentration risk on CellerateRX Surgical

“the substantial majority of our product sales revenue is derived from sales of CellerateRX Surgical.” · word for word

Weather-related shipping interruption in January impacted Q1 results; R&D spending expected to increase to 5-7% of sales annually.

“Impacted by a three-day shipping interruption in January due to a weather-related shut down; R&D expected 5-7% of sales.”

Discontinued operations risk

“Company discontinued operations of Tissue Health Plus, LLC in mid-September 2025.”

CEO transition risk

“CEO changed in September 2025; new CEO has limited tenure in role.”

Widening net loss risk

“Net loss increased from $9.7M in 2024 to $37.6M in 2025.”

Debt covenant compliance risk

“The CRG Term Loan Agreement requires us and the Guarantors to maintain compliance with certain operating and financial covenants...annual minimum revenue of at least...$75.0 million for the twelve-month period beginning on January 1, 2025 and ending on December 31, 2025.” · word for word

Concentration on CellerateRX Surgical

“CellerateRX Surgical has no comprehensive patent protection. CellerateRX Surgical may be subject to competition from the sale of substantially equivalent products that could adversely affect our business and operations.” · word for word

History of losses

“We have had a history of losses, which may continue as we expand our selling efforts.” · word for word

THP discontinuation execution risk

“Persistent losses related to THP and a lack of any firm commitments from potential investors led management and our Board of Directors to decide to discontinue THP's operations in mid-September 2025.” · word for word

Q4 net loss from continuing operations of $1.1M vs net income of $0.9M in prior year; profitability pressure in quarter.

“Net loss from continuing operations of $1.1 million, compared to net income from continuing operations of $0.9 million in the fourth quarter of 2024.” · word for word

BIASURGE sales in Q4 2024 included $1.8M from hurricane-related supply chain issues; normalized growth is lower.

“Excluding $1.8 million of BIASURGE sales related to this dynamic in the fourth quarter of 2024, net revenue in the fourth quarter of 2025 increased 13% year-over-year.” · word for word

Debt increased significantly YoY, potentially straining liquidity if growth slows.

“Long-term debt rose from $30.7M to $46.0M (+50% YoY) while cash only increased modestly.”

Revenue growth partly inflated by one-time BIASURGE sales in prior year; core growth ex-BIASURGE is lower.

“Q4 2024 included ~$1.8M BIASURGE sales due to hurricane-related shortages; excluding that, Q4 2025 growth is 11-13% vs reported 3-5%.”

Discontinuation of THP may result in write-offs or impairment.

“discontinuing operations of THP to improve its operating efficiency” · word for word

Discontinuation of THP segment indicates prior diversification strategy did not succeed; potential write-offs or transition costs.

“Sanara initiated a strategic realignment of its portfolio, ceasing operations of Tissue Health Plus ('THP') to improve the Company’s operating efficiency and reallocate resources to its core surgical business.” · word for word

Discontinued operations impairment

“Net loss from discontinued operations totaled $31.2 million and $2.7 million for the three months ended September 30, 2025 and 2024, respectively. The increase in net loss from discontinued operations for the three and nine months ended September 30, 2025 was primarily due to asset impairment charges of intangible and fixed assets related to the THP technolo” · word for word

High debt and interest expense

“The CRG Term Loan bears interest at a per annum rate equal to 13.25% ... As of September 30, 2025, there was $42.8 million of principal outstanding and $12.25 million available for future borrowing under the CRG Term Loan.” · word for word

Concentration on CellerateRX Surgical

“the substantial majority of our product sales revenue is derived from sales of CellerateRX Surgical.” · word for word